New data just released in the two largest global pharma markets show the substantial and growing level of savings made possible by increased use of generic medicines.
In developed countries, a child diagnosed with cancer has an 80% chance of surviving. Survival rates in developing countries can be as low as 10%. Dr. Mae Dolendo, a pediatric oncologist in the Philippines, is committed to evening these odds for the children she treats, with support from World Child Cancer and Sandoz.
Producing a medicine is only the first step towards getting it to the patient who needs it. The pharma industry, with its stringent requirements for product security and stability, has one of the most complex logistical chains in the world today. High-tech logistics are not just an expense, they are an investment in better access to medicines and – used efficiently – they can bring down overall healthcare costs and improve patient care.
For a growing range of therapeutic areas, biosimilars make state-of-the-art treatment more affordable1. They could be real game-changers for patients, physicians and healthcare systems.
